Hypoxia-Ischemia (HI) Model Development Service

Are you currently facing long drug development cycles, challenges in understanding complex neurological injuries, or difficulty in validating therapeutic targets for conditions like stroke or cerebral palsy? Our hypoxia-ischemia (HI) Models service helps you accelerate drug discovery, obtain high-quality, clinically relevant data, and streamline preclinical validation through advanced in vivo and in vitro HI models, comprehensive readouts, and expert scientific consultati

HI is a critical cause of devastating brain injury, particularly in vulnerable populations such as neonates, leading to conditions like Hypoxic-Ischemic Encephalopathy (HIE) and Cerebral Palsy (CP), and in adults, manifesting primarily as ischemic stroke. This complex pathological process involves a cascade of events, including excitotoxicity, oxidative stress, and inflammation, culminating in irreversible neuronal damage. Animal models, especially well-characterized rodent HI models like the Rice-Vannucci, are indispensable for unraveling HI pathophysiology, identifying novel therapeutic targets, and rigorously testing neuroprotective and neurorestorative therapies. The persistent neurological impairments observed clinically underscore the urgent need for early, effective interventions, which these models are designed to accelerate.

How Our Hypoxia-Ischemia (HI) Models Can Assist Your Project?

At CBL, we provide precise, actionable solutions that empower your neurological research. You can expect clinically relevant efficacy data for your candidate compounds, validated therapeutic targets, and deep mechanistic insights into HI-induced brain injury. Our studies deliver comprehensive reports designed to support your regulatory submissions and accelerate your journey from discovery to clinical success.

Discover How We Can Help - Request a Consultation.

Workflow: From Concept to Breakthrough Data

Our streamlined workflow ensures a collaborative and efficient research process, delivering robust and reproducible results for your project.

• Required Starting Materials:

To initiate your project, we typically require:

1. Compound Information: Detailed data on your therapeutic compound, including its chemical structure, proposed mechanism of action, and any preliminary dose range information.
2. Specific Research Questions: A clear outline of your primary research objectives and the key endpoints you aim to evaluate.
3. Prior Data (If Available): Any existing in vitro or preliminary in vivo data that can inform model selection and study design.

• Final Deliverables:

Upon project completion, you will receive:

1. Comprehensive Study Report: A detailed document encompassing the study design, methodologies, raw data, analyzed results, statistical interpretations, and a clear discussion of the findings.
2. Histological & Imaging Data: High-resolution images and quantitative analyses of brain tissue (e.g., infarct volume, neuronal counts, immunohistochemistry markers).
3. Behavioral Assessment Data: Raw data and statistical analyses from all functional and cognitive tests performed.

• Estimated Timeframe:

The typical timeframe for a standard HI model efficacy study ranges from 8 to 16 weeks, depending on the complexity of the study design, the number of compounds being evaluated, and the duration of long-term behavioral assessments required. More complex or longitudinal studies may require extended timelines.

Why Choose Us?

Choosing CBL for your Hypoxia-Ischemia research means partnering with a leader in neurological preclinical services. Our 20+ years of specialized experience, combined with our unwavering commitment to scientific excellence, sets us apart. We don't just provide data; we provide solutions backed by deep expertise and a proven track record.

Experience the Advantage - Get a Quote Today.

Customer Reviews: Real-World Impact

Exceptional Neuroprotection Data. Using CBL's HI models in our research has significantly improved our ability to identify effective neuroprotective compounds. Their precise model execution and comprehensive histological analysis provided clear, actionable data that accelerated our lead optimization. We particularly appreciate their meticulous attention to detail and the high reproducibility of their results, which is crucial for our rigorous preclinical validation process. - Dr. A*n, Senior Research Scientist, 2024

Streamlined Preclinical Validation. CBL's expertise in HI models greatly facilitated our preclinical validation efforts for a novel anti-inflammatory agent. Their team's deep understanding of HI pathophysiology and their ability to tailor study designs to our specific needs meant we gained critical insights into our compound's efficacy and mechanism of action, far beyond what we could achieve in-house. The long-term behavioral assessments were particularly insightful for understanding functional recovery. - Je Sh, Head of Preclinical Development, 2023

Unparalleled Translational Relevance. We chose CBL for our neonatal HI studies due to their reputation for clinically relevant models, and they exceeded our expectations. The data from their Rice-Vannucci model directly informed our understanding of the developmental impact of HI and helped us prioritize our therapeutic strategy. Their comprehensive biomarker analysis was invaluable for identifying potential translational markers for future clinical studies. A truly collaborative and expert partnership. - Prof. Ma Lz, Academic Researcher, 2024

Hypoxia-Ischemia (HI) Models

CBL offers a diverse portfolio of meticulously validated HI models, expertly tailored to meet the specific requirements of your research. Our models are characterized by their reproducibility, clinical relevance, and the ability to detect subtle therapeutic effects.

1. Neonatal Hypoxia-Ischemia Models

Neonatal HI is the most common cause of death and disability in human neonates, often occurring during perinatal complications, and can lead to conditions like hypoxic-ischemic encephalopathy (HIE) and is a significant cause of Cerebral Palsy (CP), resulting in severe and persistent motor, sensory, and cognitive impairments. The urgent need for early preventative or neuroprotective interventions in this vulnerable population underscores the importance of our models. Our primary model for neonatal HI is the Rice-Vannucci Model, widely recognized for its clinical translatability and its significant contribution to CP research by mimicking brain damage observed in severe CP cases:

• Unilateral Carotid Artery Ligation followed by Hypoxia: Typically performed in P7 (postnatal day 7) rat or mouse pups, this model induces a focal ischemic injury followed by systemic hypoxia, mimicking the clinical scenario of HIE and the developing brain injury associated with CP.
• Key Features: Allows for the study of acute injury, long-term neurological deficits (including those relevant to spastic CP, affecting cerebral cortex and subcortical white matter), and developmental consequences. It is highly sensitive to neuroprotective interventions.

2. Adult Hypoxia-Ischemia (Stroke) Models

Stroke, a leading cause of death and disability worldwide, often involves HI. Our adult models are designed to replicate various forms of ischemic stroke, offering high fidelity for therapeutic evaluation.

What We Can Offer

At CBL, our HI models service is designed to be your comprehensive solution for preclinical neurological research. We offer unparalleled flexibility and scientific depth to meet your specific project needs.

• Customized Model Selection: Access to a diverse range of validated HI models (neonatal Rice-Vannucci, adult tMCAO/pMCAO, global ischemia, in vitro OGD), with expert guidance to select or adapt the most appropriate model for your unique therapeutic strategy and research objectives.
• Tailored Study Design & Execution: From precise surgical induction to controlled hypoxic environments and meticulously monitored compound administration, we customize every aspect of the study to ensure optimal conditions for evaluating your therapeutic candidates.
• Comprehensive Multi-Modal Endpoints: Benefit from our extensive suite of readouts, including neurological deficit scoring, advanced in vivo imaging (MRI), detailed histopathology (neuronal loss, inflammation, apoptosis), biochemical biomarker analysis (ELISA, Western Blot, qPCR), and sophisticated long-term behavioral assessments (motor function, cognitive function).
• Flexible Compound Administration: We accommodate various routes of administration (e.g., intravenous, intraperitoneal, oral) and dosing regimens, ensuring the precise delivery and evaluation of your therapeutic agents.
• Expert Scientific Consultation: Our team of seasoned biologists and neurologists provides continuous scientific guidance, from initial study design and protocol optimization to in-depth data interpretation and strategic recommendations, ensuring your project's success.
• Rigorous Quality Control & Reproducibility: Our commitment to the highest standards of animal welfare, experimental consistency, and data integrity ensures that you receive highly reproducible and reliable results, critical for robust preclinical validation.
• Complete Data Packages: Receive comprehensive, publication-ready reports with detailed methodologies, raw data, statistical analyses, and clear conclusions, supporting your internal decision-making and regulatory submissions.
• Long-Term Follow-up Studies: Extend your research to evaluate chronic effects and long-term functional recovery, providing a more complete picture of your compound's therapeutic potential.

Related Services

To further support your comprehensive neurological research and drug development goals, CBL offers a range of complementary services that can be seamlessly integrated with our Hypoxia-Ischemia Models:

• Neuroinflammation Research Services: Many HI injuries involve significant neuroinflammatory responses. Explore our specialized services for targeting and modulating neuroinflammation.
• Neurodegenerative Disease Models: For broader neurological research, consider our extensive portfolio of models for various neurodegenerative conditions.
• Biomarker Discovery & Validation: Enhance the translational potential of your findings with our advanced biomarker discovery and validation services.

Ready to discuss your next breakthrough? Our team of expert scientists is eager to collaborate with you.

Contact Our Team for More Information and to Discuss Your Project.